268 related articles for article (PubMed ID: 18826953)
1. Identifying key components of the PrPC-PrPSc replicative interface.
Abalos GC; Cruite JT; Bellon A; Hemmers S; Akagi J; Mastrianni JA; Williamson RA; Solforosi L
J Biol Chem; 2008 Dec; 283(49):34021-8. PubMed ID: 18826953
[TBL] [Abstract][Full Text] [Related]
2. Mouse prion protein (PrP) segment 100 to 104 regulates conversion of PrP(C) to PrP(Sc) in prion-infected neuroblastoma cells.
Hara H; Okemoto-Nakamura Y; Shinkai-Ouchi F; Hanada K; Yamakawa Y; Hagiwara K
J Virol; 2012 May; 86(10):5626-36. PubMed ID: 22398286
[TBL] [Abstract][Full Text] [Related]
3. The charge structure of helix 1 in the prion protein regulates conversion to pathogenic PrPSc.
Norstrom EM; Mastrianni JA
J Virol; 2006 Sep; 80(17):8521-9. PubMed ID: 16912302
[TBL] [Abstract][Full Text] [Related]
4. Toward molecular dissection of PrPC-PrPSc interactions.
Solforosi L; Bellon A; Schaller M; Cruite JT; Abalos GC; Williamson RA
J Biol Chem; 2007 Mar; 282(10):7465-71. PubMed ID: 17218310
[TBL] [Abstract][Full Text] [Related]
5. Prion protein self-peptides modulate prion interactions and conversion.
Rigter A; Priem J; Timmers-Parohi D; Langeveld JP; van Zijderveld FG; Bossers A
BMC Biochem; 2009 Nov; 10():29. PubMed ID: 19943977
[TBL] [Abstract][Full Text] [Related]
6. Disulfide-crosslink scanning reveals prion-induced conformational changes and prion strain-specific structures of the pathological prion protein PrP
Taguchi Y; Lu L; Marrero-Winkens C; Otaki H; Nishida N; Schatzl HM
J Biol Chem; 2018 Aug; 293(33):12730-12740. PubMed ID: 29934306
[TBL] [Abstract][Full Text] [Related]
7. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc.
Moroncini G; Kanu N; Solforosi L; Abalos G; Telling GC; Head M; Ironside J; Brockes JP; Burton DR; Williamson RA
Proc Natl Acad Sci U S A; 2004 Jul; 101(28):10404-9. PubMed ID: 15240877
[TBL] [Abstract][Full Text] [Related]
8. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
9. Virus Infection, Genetic Mutations, and Prion Infection in Prion Protein Conversion.
Hara H; Sakaguchi S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830321
[TBL] [Abstract][Full Text] [Related]
10. Identifying critical sites of PrP(c)-PrP(Sc) interaction in prion-infected cells by dominant-negative inhibition.
Taguchi Y; Schätzl HM
Prion; 2013; 7(6):452-6. PubMed ID: 24401595
[TBL] [Abstract][Full Text] [Related]
11. Immunological mimicry of PrPC-PrPSc interactions: antibody-induced PrP misfolding.
Li L; Guest W; Huang A; Plotkin SS; Cashman NR
Protein Eng Des Sel; 2009 Aug; 22(8):523-9. PubMed ID: 19602568
[TBL] [Abstract][Full Text] [Related]
12. The octarepeat region of the prion protein is conformationally altered in PrP(Sc).
Yam AY; Gao CM; Wang X; Wu P; Peretz D
PLoS One; 2010 Feb; 5(2):e9316. PubMed ID: 20195363
[TBL] [Abstract][Full Text] [Related]
13. Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds.
Phuan PW; Zorn JA; Safar J; Giles K; Prusiner SB; Cohen FE; May BCH
J Gen Virol; 2007 Apr; 88(Pt 4):1392-1401. PubMed ID: 17374787
[TBL] [Abstract][Full Text] [Related]
14. The role of rafts in the fibrillization and aggregation of prions.
Pinheiro TJ
Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
[TBL] [Abstract][Full Text] [Related]
15. Generation of monoclonal antibody that distinguishes PrPSc from PrPC and neutralizes prion infectivity.
Horiuchi M; Karino A; Furuoka H; Ishiguro N; Kimura K; Shinagawa M
Virology; 2009 Nov; 394(2):200-7. PubMed ID: 19766283
[TBL] [Abstract][Full Text] [Related]
16. Recombinant prion protein refolded with lipid and RNA has the biochemical hallmarks of a prion but lacks in vivo infectivity.
Timmes AG; Moore RA; Fischer ER; Priola SA
PLoS One; 2013; 8(7):e71081. PubMed ID: 23936256
[TBL] [Abstract][Full Text] [Related]
17. The AGAAAAGA palindrome in PrP is required to generate a productive PrPSc-PrPC complex that leads to prion propagation.
Norstrom EM; Mastrianni JA
J Biol Chem; 2005 Jul; 280(29):27236-43. PubMed ID: 15917252
[TBL] [Abstract][Full Text] [Related]
18. Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.
Katorcha E; Makarava N; Savtchenko R; D'Azzo A; Baskakov IV
PLoS Pathog; 2014 Sep; 10(9):e1004366. PubMed ID: 25211026
[TBL] [Abstract][Full Text] [Related]
19. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human prion protein inhibits prion propagation in vitro.
Yuan J; Zhan YA; Abskharon R; Xiao X; Martinez MC; Zhou X; Kneale G; Mikol J; Lehmann S; Surewicz WK; Castilla J; Steyaert J; Zhang S; Kong Q; Petersen RB; Wohlkonig A; Zou WQ
Sci Rep; 2013 Oct; 3():2911. PubMed ID: 24105336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
